Inclusion Criteria:

- Patient provides written Informed Consent and is willing to comply with protocol
requirements

- Patient is at least 18 years of age on the day of dosing (male or female of any race
or ethnicity)

- Patient is capable of lying still in the PET scanner for the protocol required time
frame(s)

- Patient has a diagnosis of one of the following malignancies using the TNM Staging
System:

- Lung cancer (T3 grade up, node positive, but no metastatic disease)

- Head and neck cancer (T3 grade up, node positive, but no metastatic disease)

- Patient has undergone a comparative, diagnostic procedure with lesion(s) visible,
other than ultrasound, that includes, but is not limited to computed tomography (CT),
magnetic resonance imaging (MRI), nuclear medicine imaging, endoscopy, laparoscopy,
standard abdominal x-ray, biopsy and/or surgery for one of the above mentioned areas

- Patient is scheduled to start radiotherapy or a chemoradiotherapy regimen for
curative intent

- As a part of his/her standard radiotherapy or chemoradiotherapy regimen, patient is
scheduled to have clinical [F-18]FDG PET scans pre treatment and post treatment (at
about 4 weeks (±1 week) after the start of therapy)

- Patient is scheduled to have the investigational, pre treatment [F-18] FLT PET scan
recommended to be within ± 2 days of the clinical, pre treatment [F-18] FDG PET scan

- Patient has not received or intends to receive 5-fluorouracil (chemotherapeutic
agent)

- Patient has a score of greater than or equal to (>/=) 60% on the Karnofsky
Performance Status Scale

Exclusion Criteria:

- Patient is a pregnant or lactating female. Exclude the possibility of pregnancy:

- by testing on site at the institution (serum or urine βHCG) within 48 hours prior
to the start of each investigational product administration

- by surgical history (eg, tubal ligation or hysterectomy)

- by patient's history of being post menopausal with a minimum 1 year without menses

- Patient is undergoing treatment with palliative intent

- Patient has received an investigational compound and/or medical device within 14 days
before admission into this study

- Patient has any medical condition or other circumstances which would significantly
decrease the chances of obtaining reliable data, achieving study objectives, or
completing the study and/or post-dose follow-up examinations

- Patient is determined by the Investigator that he/she is clinically unsuitable for
the study.